Corticosteroid Insulin Formulation for Bone Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoarthritis, bone fractures, and jaw tumors and cysts are invasive, costly, and often ineffective in promoting significant regeneration of damaged tissues, with a lack of minimally invasive methodologies that can effectively stimulate bone, cartilage, and periodontium regeneration.
Innovation Solution
A formulation comprising a corticosteroid and an insulin analog, such as dexamethasone and insulin lispro, is used in a non-surgical and minimally invasive method to stimulate regeneration of injured bone, cartilage, and periodontium, and treat tumors and cysts by contacting the affected areas with the formulation, which includes organic acids like citric acid.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If surgical treatments such as autologous chondrocyte implantation are used for cartilage regeneration, then cartilage re-growth can be achieved, but the treatment is expensive and time-consuming
Solution Approach 1:
The patent changes the chemical parameters of the treatment by using a specific formulation containing dexamethasone (0.4-2.0 mg/mL) and insulin lispro (0.001-0.01 U/mL) to accelerate cartilage regeneration, transforming the treatment from a long-term surgical process to a shorter pharmacological intervention while maintaining effectiveness
2Reliability
If surgical treatments such as osteotomies and joint replacement are used for osteoarthritis, then symptomatic relief can be achieved, but the cost is very high and results often do not meet expectations
Solution Approach 1:
The patent replaces mechanical surgical interventions (osteotomies, joint replacement) with a pharmacological chemical system consisting of corticosteroid and insulin analog formulation, eliminating the need for complex surgical procedures while achieving comparable or superior therapeutic outcomes at lower cost
3Reliability
If immobilization is used for bone fracture management, then consolidation can be ensured, but pseudarthrosis may occur due to instability, infection, or bone mass loss
Solution Approach 1:
The patent introduces a pharmacological intermediary (dexamethasone and insulin lispro formulation) that mediates between the fracture site and the healing process, promoting bone regeneration and consolidation while reducing the risk of pseudarthrosis by enhancing cellular activity and bone formation at the fracture site
4Reliability
If bisphosphonates are used to treat osteoporosis, then bone resorption is reduced, but side effects such as esophageal irritation, osteonecrosis of the jaw, and atypical femoral fractures occur
Solution Approach 1:
The patent changes the pharmacological parameters by using a different mechanism of action - combining corticosteroid (anti-inflammatory) and insulin analog (metabolic regulation) instead of bisphosphonates (bone resorption inhibition) - achieving bone strength improvement through enhanced bone formation and metabolism without the harmful side effects of bisphosphonates
Data Source
AI summary
The present invention provides a formulation comprising a corticosteroid and an insulin analog or pharmaceutical compositions thereof. Also provided is a formulation comprising a corticosteroid, insulin lispro and at least one organic acid or pharmaceutical compositions thereof. The present invention provides methods for stimulating bone and/or cartilage growth, for treating tendon and/or ligament damage, for stimulating hair growth and/or reducing hair loss, for stimulating growth of a tooth and/or periodontium and for treating tumors and cysts of the jaw by administering the formulations described herein.